Brief: Diasorin Receives Us' FDA 510(K) Clearance And Clia Waiver For Liaison Nes Group A Streptococcus (Gas) Assay
19/06/2026 14:59
BRIEF-Diasorin Receives Us' FDA 510(K) Clearance And Clia Waiver For Liaison Nes Group A Streptococcus (Gas) Assay June 19 (Reuters) - Diasorin SpA DIAS.MI:
RECEIVES US' FDA 510(K) CLEARANCE AND CLIA WAIVER FOR LIAISON NES GROUP A STREPTOCOCCUS (GAS) ASSAY
Further company coverage: DIAS.MI
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Diasorin
See all newsEquita upgrades Diasorin, sees 'solid' Q3
Brief: Diasorin Obtained FDA Approval For Fully Automated Laboratory Serology Tests For Human Parvovirus B19 Igm And Human Parvovirus B19 Igg On The Liaison Xl
Europe Research Roundup: Allianz, Mercedes-Benz, Tesco
European life sciences stocks rise on strong sector momentum
Italy - Factors to watch on September 21